Phreesia, Inc. $PHR Shares Acquired by Moody National Bank Trust Division

Key Points

• Moody National Bank Trust Division increased its stake in Phreesia, Inc. by 19.3% during the second quarter, owning 115,317 shares worth approximately $3.28 million.
• Insider Evan Roberts sold 45,147 shares of Phreesia, representing a 5.84% decrease in their ownership.
• Phreesia has received several upgrades from analysts, with DA Davidson upgrading the stock to a "strong buy" rating and a consensus price target of $34.08.

Moody National Bank Trust Division raised its stake in Phreesia, Inc. (NYSE:PHR - Free Report) by 19.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 115,317 shares of the company's stock after acquiring an additional 18,652 shares during the quarter. Moody National Bank Trust Division owned approximately 0.19% of Phreesia worth $3,282,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Cubist Systematic Strategies LLC acquired a new stake in Phreesia in the 1st quarter valued at about $774,000. Principal Financial Group Inc. purchased a new stake in shares of Phreesia in the first quarter worth about $1,623,000. Deutsche Bank AG raised its stake in Phreesia by 95.9% during the fourth quarter. Deutsche Bank AG now owns 57,297 shares of the company's stock valued at $1,442,000 after buying an additional 28,047 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Phreesia by 105.2% during the first quarter. Acadian Asset Management LLC now owns 225,317 shares of the company's stock valued at $5,754,000 after purchasing an additional 115,527 shares during the last quarter. Finally, Bessemer Group Inc. raised its stake in shares of Phreesia by 23.2% in the 1st quarter. Bessemer Group Inc. now owns 47,758 shares of the company's stock worth $1,222,000 after buying an additional 8,978 shares in the last quarter. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Phreesia Stock Down 1.0%

Shares of PHR stock traded down $0.25 on Tuesday, reaching $24.49. 225,076 shares of the company's stock traded hands, compared to its average volume of 602,817. The business's 50 day moving average price is $27.51 and its two-hundred day moving average price is $26.40. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.12 and a current ratio of 2.12. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $32.76. The company has a market capitalization of $1.47 billion, a P/E ratio of -59.25 and a beta of 0.72.

Phreesia (NYSE:PHR - Get Free Report) last released its quarterly earnings results on Thursday, September 4th. The company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.08. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.The business had revenue of $117.26 million for the quarter, compared to analyst estimates of $116.39 million. During the same period in the prior year, the company earned ($0.03) EPS. Phreesia's revenue for the quarter was up 14.9% on a year-over-year basis. Phreesia has set its FY 2026 guidance at EPS. On average, equities analysts forecast that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Insider Activity at Phreesia

In other Phreesia news, General Counsel Allison C. Hoffman sold 3,133 shares of the stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $23.28, for a total value of $72,936.24. Following the completion of the sale, the general counsel owned 139,037 shares in the company, valued at approximately $3,236,781.36. This trade represents a 2.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Mark Douglas Smith sold 7,000 shares of the firm's stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $29.00, for a total transaction of $203,000.00. Following the completion of the transaction, the director directly owned 37,353 shares of the company's stock, valued at approximately $1,083,237. The trade was a 15.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 128,343 shares of company stock worth $3,739,343. 5.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Stephens reaffirmed an "overweight" rating and issued a $32.00 price target on shares of Phreesia in a research report on Wednesday, September 3rd. Mizuho began coverage on shares of Phreesia in a report on Wednesday, August 27th. They set an "outperform" rating and a $36.00 target price on the stock. Citigroup restated an "outperform" rating on shares of Phreesia in a report on Monday, September 8th. Truist Financial upped their price objective on shares of Phreesia from $35.00 to $36.00 and gave the stock a "buy" rating in a research report on Friday, September 5th. Finally, Piper Sandler increased their price target on shares of Phreesia from $33.00 to $34.00 and gave the stock an "overweight" rating in a report on Friday, September 5th. One analyst has rated the stock with a Strong Buy rating and twelve have given a Buy rating to the company's stock. Based on data from MarketBeat, Phreesia has an average rating of "Buy" and an average target price of $34.08.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.